Long-term response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer: a case report

The infrequency of cases, limited guidelines, and lack of robust trials have delayed therapeutic advancements in vulvar cancer, a rare gynecologic malignancy. Here, we present a case of a 52-year-old woman with human papillomavirus–positive vulvar squamous cell carcinoma with metastases to the lung. After experiencing disease progression despite surgery and different chemotherapy combinations, smuhe enrolled in a phase I trial of relacorilant, a selective glucocorticoid receptor antagonist, plus nab-paclitaxel treatment. She experienced a remarkable response to this treatment regimen and has maintained long-term benefit for >8 years.